Explore the words cloud of the ESCulab project. It provides you a very rough idea of what is the project "ESCulab" about.
The following table provides information about the project.
Coordinator |
STICHTING LYGATURE
Organization address contact info |
Coordinator Country | Netherlands [NL] |
Total cost | 36˙729˙319 € |
EC max contribution | 18˙249˙992 € (50%) |
Programme |
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2)) |
Code Call | H2020-JTI-IMI2-2017-12-two-stage |
Funding Scheme | IMI2-RIA |
Starting year | 2018 |
Duration (year-month-day) | from 2018-12-01 to 2023-11-30 |
Take a look of project's partnership.
By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific insights into innovative drug starting points. New biological ideas will be collected by crowdsourcing, novel targets, phenotypes and pathways translated and de-risked by delivering high-quality chemical starting points for drug development. Innovators from EU academics and SMEs are offered access to state-of-the-art industry-grade facilities, drug discovery expertise, and a top-quality, curated library with over 550,000 unique compounds suitable for screening potential drug targets. The ESCulab drug discovery data generated will allow the innovators to build a proposition that is likely to attract investors and/or drug developers and stimulate them to further exploit these findings. Ultimately, this will result in novel medicines – based on basic scientific findings – that will help patients (sooner).
ESCulab will achieve this by starting off the shoulders of the European Lead Factory (ELF), where this principle has been successfully implemented. 15 out of the 18 ESCulab consortium members were involved in ELF, thus ensuring maximum benefit from the ELF legacy. ESCulab will expand and enhance ELF by supporting 185 new screens. Important additions include the application of a much larger compound collection for screening, the ability to accommodate the more complex phenotypic screening assays, and the building of a sustainable business model to ensure access to Collaborative Drug Discovery activities beyond the funding period. The delivery of qualified hit lists (QHLs) is the end point for this project, but during the funding period, ESCulab will attract additonal funding for externally paid screens and hit-to-lead projects for organizations such as charities and foundations for long term sustainability of the initiative.
Report on the establishment of an Ethics Advisory Board | Documents, reports | 2020-04-02 08:51:33 |
Report on the establishment of a secure IT platform for sharing project documents | Documents, reports | 2020-03-27 11:47:40 |
Report on delivery of 1st screening sets to all 10 screening centres | Documents, reports | 2020-03-27 11:45:30 |
Report on the establishment of a Legal and IP committee | Documents, reports | 2020-03-27 11:47:33 |
Report on the HDB implementation for HCS | Documents, reports | 2020-03-27 11:47:49 |
Report on established Sharepoint environment for secure data sharing outside the HDB | Documents, reports | 2020-03-27 11:47:57 |
Report on application process being operational | Documents, reports | 2020-03-27 11:47:14 |
Annual update on communication and dissemination activities (1) | Documents, reports | 2020-03-27 11:45:49 |
Annual report on recruitment activities and number of submitted proposals (1) | Documents, reports | 2020-03-27 11:45:06 |
Annual report on project output and post-QHL processes (1) | Documents, reports | 2020-03-27 11:46:30 |
Project website established | Websites, patent fillings, videos etc. | 2020-03-27 11:46:36 |
Report on the HDB implementation for HTS at all ESCulab screening centres | Documents, reports | 2020-03-27 11:44:57 |
Report on the created communication and recruitment material | Documents, reports | 2020-03-27 11:46:20 |
Annual update on the programme portfolio statistics (1) | Documents, reports | 2020-03-27 11:46:07 |
Report on implementation of recruitment plan at 3 regional/national life science organizations | Documents, reports | 2020-03-27 11:45:22 |
Take a look to the deliverables list in detail: detailed list of ESCulab deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ESCULAB" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ESCULAB" are provided by the European Opendata Portal: CORDIS opendata.
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Read MoreProgress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Read More